Redwood Ventures — 2020 Investments
3 investments dated 2020 · listed companies and verified rows first · show all
Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.
BiotechCambridge, GB
Louise Modis(Chief Executive Officer)inMartin Pass(Chief Development Officer)inGiles Brown(Executive VP Drug Discovery)in
Co-investorsAdvent Life SciencesNovartis Venture FundSV Health InvestorsDementia Discovery FundEuropean Investment FundForbion+2 more
Atexto provides audio-to-text transcription services through an online platform.
Developer ToolsFuture of Work
Esteban Gorupicz
Co-investors500 GlobalMC CapitalAvalancha VenturesDux CapitalInnogen Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rappta Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.